李念光

发布者:石乔梓发布时间:2024-07-18浏览次数:639


姓名:李念光

职称:教授

E-maillinianguang@163.com           

主要研究方向:血液肿瘤新药物分子发现及优化


个人简介

李念光,教授,博士生导师,现任南京中医药大学药学院副院长,江苏省药学会药物化学专业委员会委员,南京市药学会药物化学与药物分析专业委员会副主任委员。2007年博士毕业于中国药科大学,2012年赴美国哈佛大学进行访学和合作研究。2011年入选江苏省333人才培养第三层次培养对象,2012年入选“教育部新世纪优秀人才支持计划”,2013年入选江苏省第十批“六大人才高峰”,2013年获教育部霍英东青年教师奖三等奖。近年来主要从事血液肿瘤新药物分子的设计与合成研究,主持10多项国家及省部级项目,在Journal of Experimental & Clinical Cancer ResearchJournal of Medicinal ChemistryEuropean Journal of Medicinal Chemistry等杂志发表SCI论文100余篇。申请国家发明专利11项,授权9项。指导本科生获大学生“挑战杯”课外学术竞赛国家级二等奖2项,研究生获江苏省优秀毕业论文1次,担任本科教学《药物化学》、《药物合成》以及研究生教学《药物化学专论》、《药物合成化学》课程负责人。


承担的主要科研项目

1. 国家自然科学基金面上项目(82373710),新型构象稳定的大环类FLT3抑制剂的设计、合成与抑制门控卡口氨基酸F691L突变导致的急性髓性白血病耐药活性研究,2024/01-2027/12,主持,49


2. 国家自然科学基金面上项目(81973171),基于结构的新型选择性FLT3共价抑制剂的设计、合成及其对(复发性及预后不良)急性髓性白血病的生物活性研究,2020/01-2023/12,主持,55


3. 国家重点研发计划子课题(2020YFA0509404),靶向肝、肺转移定植中特化外秘体活性小分子探针的发现和干预研究,2020/11-2025/10,主持,20


4. 江苏省自然科学基金(BK20151563),治疗阿尔茨海默病的新型多靶向BACE1抑制剂的设计、合成及其作用机制研究,2015/07-2018/06,主持,10


5. 江苏省第十批“六大人才高峰”项目A类资助(2013-YY-010),以天然产物为模板的新型凝血酶抑制剂的设计、合成与生物活性研究,2014/01-2016/12,主持,15


6. 教育部新世纪优秀人才支持计划(NCET-12-0741),天然产物的化学合成及其构效关系,2013/01-2015/12,主持,50


7. 国家自然科学基金(81001382),基于体内代谢机制的灯盏乙素苷元结构修饰、构效关系及生物利用度研究,2011/01-2013/12,主持,21




代表性论文

1. Yan-Cheng Yu, Zhen-Jiang Tong, Xiao-Ting Liang, Jia-Zhen Wu, Yu-Jing Xu, Jing-Jing Wang, Meng-Yuan Zhang, Tian-Hua Wei, Jin Yang, Yi-Bo Wang, Qing-Xin Wang, Qing-Qing Li, Zi-Xuan Wang, Xue-Jiao Leng, Ning Ding, Xin Xue, Shan-Liang Sun, Nian-Guang Li*, XiaoLong Wang*. Discovery of RORγ Allosteric Fluorescent Probes and the Application: Fluorescence Polarization, Screening and Bioimaging. Journal of Medicinal Chemistry, 2024, 67(5), 41944224. (IF 7.300)

2. Zi-Xuan Wang, Qing-Qing Li, Jiao Cai, Jia-Zhen Wu, Jing-Jing Wang, Meng-Yuan Zhang, Qing-Xin Wang, Zhen-Jiang Tong, Jin Yang, Tian-Hua Wei, Yun Zhou, Wei-Chen Dai, Ning Ding, Xue-Jiao Leng, Shan-Liang Sun, Xin Xue, Yan-Cheng Yu*, Ye Yang*, Nian-Guang Li*, Zhi-Hao Shi*. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Journal of Medicinal Chemistry, 2024, 67(6), 6, 4346-4375. (IF 7.300)

3. Shan-Liang Sun, Shi-Han Wu, Ji-Bo Kang, Yi-Yuan Ma, Lu Chen, Peng Cao,* Liang Chang, Ning Ding, Xin Xue,* Nian-Guang Li,* and Zhi-Hao Shi* Medicinal chemistry strategies for the development of Bruton’s tyrosine kinase inhibitors against resistance. Journal of Medicinal Chemistry, 2022, 65, 7415−7437. (IF 7.300)

4. Yue Zhong, Run-Ze Qiu, Shan-Liang Sun,* Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li,* Zhi-Hao Shi*. Small-molecule Fms-like tyrosine kinase 3 inhibitors: An attractive and efficient method for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 2020, 63(21), 12403−12428. (IF 7.300)

5. Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li*, Yibei Xiao*, Jinao Duan*, Ye Yang*. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. Journal of Experimental & Clinical Cancer Research, 2022, 41:11. (IF 11.300)

6. Shan-Liang Sun, Jia-Zhen Wu, Jing-Jing Wang, Hai Zhou, Chen-Qian Zhang, Zhen-Jiang Tong, Yi-Bo Wang, Jiu-Kai Sha, Qing-Xin Wang, Jia-Chuan Liu, Xin-Rui Zheng, Qing-Qing Li, Meng-Yuan Zhang, Jin Yang, Tian-Hua Wei, Zi-Xuan Wang, Yan-Cheng Yu, Ning Ding, Xue-Jiao Leng, Xin Xue, He-Min Li, Wei-Chen Dai, Xiao-Ying Yin, Ye Yang*, Jin-Ao Duan*, Nian-Guang Li*, Zhi-Hao Shi*. Preclinical Characterization of Danatinib as a Novel FLT3 Inhibitor with Excellent Efficacy Against Resistant Acute Myeloid Leukemia. Biomedicine & Pharmacotherapy, 2023, 169, 115905. (IF 7.500)

7. Jiaojiao Wang, Dihui Xu, Lili Shen, Jing Zhou, Xiang Lv, Hongyue Ma*, Nianguang Li*, Qinan Wu, Jinao Duan. Anti-inflammatory and analgesic actions of bufotenine through inhibiting lipid metabolism pathway. Biomedicine & Pharmacotherapy, 2021, 140, 111749. (IF 7.500)

8. Qing-Xin Wang, Peng-Yu Zhang, Qing-Qing Li, Zhen-Jiang Tong, Jia-Zhen Wu, Shao-Peng Yu, Yan-Cheng Yu, Ning Ding, Xue-Jiao Leng, Liang Chang, Jin-Guo Xu, Shan-Liang Sun*, Ye Yang*, Nian-Guang Li*, Zhi-Hao Shi*. Challenges for the Development of Mutant Isocitrate Dehydrogenases 1 Inhibitors to Treat Glioma. European Journal of Medicinal Chemistry, 2023, 257, 115464. (IF 6.700)

9. Jing-Han Zhao, Yue-Wei Wang, Jin-Yang, Zhen-Jiang Tong, Jia-Zhen Wu, Yi-Bo Wang, Qing-Xin Wang, Qing-Qing Li, Zi-Xuan Wang, Yan-Cheng Yu, Xue-Jiao Leng, Liang Chang, Xin Xue, Shan-Liang Sun, He-Min Li, Chun-Lei Xu, Ning Ding*, Jin-Ao Duan*, Nian-Guang Li*, Zhi-Hao Shi*. Natural products as potential lead compounds to develop new antiviral drugs over the past decade. European Journal of Medicinal Chemistry, 2023, 260, 115726. (IF 6.700)

10. Xin Xue, Ji-Bo Kang, Xiao Yang, Nan Li, Liang Chang*, Juan Ji, Xiang-Kai Meng, Hai-Qing Zhang, Yue Zhong, Shao-Peng Yu, Wen-Yu Wu, Xiao-Long Wang, Nian-Guang Li*, Shan-Liang Sun*. An efficient strategy for digging protein-protein interactions for rational drug design–A case study with HIF-1α/VHL. European Journal of Medicinal Chemistry, 2022, 227, 113871. (IF 6.700)









南中医药学院南中医药学院学子南中医药学院研究生